Talent PPT group (00760) released its interim performance, with a shareholder's attributable loss of 49.845 million yuan, a 27.83% increase year-on-year.
Talent ppt gp (00760) announced its interim performance for the six months ended June 30, 2024, with group revenue...
Talent PPT GP (00760.HK) plans to hold a board of directors meeting on August 29th to approve mid-year performance.
Board of directors of Talent PPT GP (00760.HK) announced that a meeting will be held on Thursday, August 29, 2024 at 3 pm to consider and approve (including) the unaudited consolidated financial statements and mid-term performance for the period of 6 months ending June 30, 2024 of the company and its subsidiaries.
Newland Pharmaceutical: Summary of Half-Year Report in 2024.
Newland Pharmaceutical: Half-year report for the year 2024.
New World (301277.SZ): net income of 1.12 billion yuan in the first half of the year, a year-on-year increase of 18.98%.
New World (301277.SZ) announced its 2024 semi-annual report. During the reporting period, the company further strengthened internal management, adhered to cost reduction and efficiency increase, and achieved revenue of CNY 0.397 billion, an increase of 18.74% year-on-year; achieving net income of CNY 0.112 billion attributable to shareholders of the listed company, an increase of 18.98% year-on-year; net income attributable to shareholders of the listed company after deducting non-recurring gains and losses was CNY 0.105 billion, an increase of 22.34% year-on-year; basic earnings per share was CNY 0.40. With the construction of the company's annual output of 120 tons of active pharmaceutical ingredients, the research and development center construction project and the Asia vets.
Xintiandi (301277.SZ): 2.1 million shares issued before the initial public offering will be lifted on July 15th.
On July 11th, Gelunhui announced a notice about the partial lifting of the restricted shares for the first issuance of public shares. There was only one shareholder for this partial lifting, involving a total of 2.1 million shares, which accounts for 0.7499% of the company's total share capital. The lifting date for the restricted shares is July 15, 2024 (Monday).
Xintian Real Estate Group (00760.HK): The subsidiary Yongxiang received a letter from SHKP
Gelonghui, June 2, 丨 Xintian Real Estate Group (00760.HK) announced that on May 31, 2024, Yongxiang, a wholly-owned subsidiary of the company (holding 30% of Guangzhou Xintian's shares), received a letter from Xindi (a company holding the remaining 70% of Guangzhou Xintian's shares). The letter argues that, according to the terms of the framework agreement, given that (i) Yongxiang is mainly responsible for coordinating the work of the relocation and resettlement area, (ii) the costs related to the relocation and resettlement area paid by Guangzhou Xintian have exceeded the estimated cost at the beginning of the cooperation, and (iii) Xindi, as the holder of 70% of Guangzhou Xintian's shares, has indirectly borne such overspent costs,
Xintiandi (301277.SZ): Pharmaceutical production license changes mainly involve increasing commissioned production
Gelonghui, May 21丨Xintiandi (301277.SZ) announced that the company (hereinafter referred to as the “Company”) recently obtained a “Pharmaceutical Production License” issued by the Henan Drug Administration and agreed to the “Pharmaceutical Production License” change application. This change mainly involves an increase in contract production; other details remain unchanged. Additional commissioned items: Trustee Company: Baizheng Pharmaceutical Co., Ltd.; Commissioned Variety: Moxifloxacin Hydrochloride Tablets (Specification: 0.4g); Commissioned Production Address: No. 3888 Xuyou East Road, Dongcheng District, Xuchang City; Commissioned Production Workshop and Production Line: Tablet Workshop, General Production Line. (Pharmaceuticals only
Xintian Real Estate Group (00760.HK) proposes share capital restructuring
Gelonghui, May 10, 丨 Xintian Real Estate Group (00760.HK) announced that the company proposes to carry out and implement a share capital restructuring, which will involve the following steps: (a) share capital reduction, which will involve reducing the company's issued share capital by canceling HK$0.07 per issued share to reduce the company's issued share capital, so that the face value of each issued share will be reduced from HK$0.08 to HK$0.01; (b) pending and immediately after the share capital reduction, the shares will be split. Unissued shares with a face value of HK$0.08 per share were split into 8 shares per share Face value 0.0
Xintiandi (301277.SZ): No technological achievements have been formed in synthetic biotechnology that can be industrialized
Gelonghui, May 7 | Xintiandi (301277.SZ) said on the investor interactive platform that up to now, the company has not achieved technological achievements that can be industrialized in synthetic biotechnology.
Newland Pharmaceutical Co., Ltd. (SZSE:301277) Looks Like A Good Stock, And It's Going Ex-Dividend Soon
Xintiandi (301277.SZ): Net profit of 559.181,000 yuan in the first quarter increased 19.69% year-on-year
Gelonghui, April 23 | Xintiandi (301277.SZ) released its report for the first quarter of 2024. Operating revenue for the reporting period was 185 million yuan, up 6.98% year on year; net profit attributable to shareholders of listed companies was 559.181,000 yuan, up 19.69% year on year; net profit attributable to shareholders of listed companies after deducting non-recurring profit and loss was 52,2691,000 yuan, up 22.37% year on year; basic earnings per share were 0.28 yuan.
Coastal Homes subsidiary signs share transfer agreement with Liang Xiaodong
Coastal Homes (01124) issued an announcement. On March 27, 2024, the seller Fengying Global Investment Co., Ltd. (a wholly-owned subsidiary of the company) signed a share transfer agreement with the buyer Liang Xiaodong. The seller has agreed to sell shares conditionally, and the buyer has agreed to buy and sell shares at a total cost of HK$10,000 in accordance with the terms of the share transfer agreement (equivalent to the total number of issued shares of the company sold). According to reports, the selling company Qifeng Development Co., Ltd. was an indirect wholly-owned subsidiary of the company on the date of this announcement and immediately before completion. The selling company is mainly engaged in investment holding, and its subsidiaries are mainly engaged in property development and investment control
Xintiandi (301277.SZ): Obtained a notice of approval for the marketing application of chemical raw materials
Gelonghui announced on April 8, Xintiandi (301277.SZ) that on April 2, 2024, the company received the “Notice of Approval of the Marketing Application for Chemical Ingredients” for esomeprazole magnesium raw materials approved and issued by the State Drug Administration.
Improved Earnings Required Before Newland Pharmaceutical Co., Ltd. (SZSE:301277) Shares Find Their Feet
Hualian Co., Ltd. (000882.SZ): Yinchuan Hualian plans to purchase Basement 101 of Yuehai Xintiandi Shopping Plaza, No. 13 (formerly B1), Kangping Road, Kangping Road, Jinfeng District, Yinchuan, for 114 million yuan
Gelonghui Co., Ltd. (000882.SZ) announced that its wholly-owned subsidiary, Yinchuan Hualian Shopping Mall Co., Ltd. (“Yinchuan Hualian”), recently signed an “Asset Sale Agreement” with Yinchuan Hailong Xingda Commercial Co., Ltd. (“Yinchuan Hailong Xingda”). Yinchuan Hualian plans to buy YINCHUAN HAIRONGXINGDA for 114 million yuan (formerly known as “Target Assets”) of Yinchuan Hailong Xingda (formerly “Target Assets”)”) Real estate.
Xintiandi (301277.SZ): Net profit for 2023 increased 20.16% to 159 million yuan, plans to transfer 4 yuan to 10 to 4 yuan
Gelonghui, March 25 | Xintiandi (301277.SZ) announced its 2023 annual report. In 2023, the company achieved operating income of 651 million yuan, up 3.84% year on year; net profit attributable to shareholders of listed companies was 159 million yuan, up 20.16% year on year; net profit attributable to shareholders of listed companies after deducting non-recurring profit and loss was 144 million yuan, up 11.14% year on year; basic income per share was 0.79 yuan; it is proposed to distribute 4 yuan (tax included) for every 10 shares to all shareholders with capital reserve funds .
Xintian Real Estate Group (00760.HK) plans to hold a board meeting on March 27 to consider and approve the annual results
Gelonghui, March 13, 丨 Xintian Real Estate Group (00760.HK) announced that the board meeting will be held at 3:00 p.m. on March 27, 2024 (Wednesday) to consider and approve (including) the audited consolidated financial statements and annual results announcements of the company and its subsidiaries for the year ended 31 December 2023.
Xintiandi (301277.SZ): The active ingredient moxifloxacin hydrochloride passed the drug GMP compliance inspection
Gelonghui, Feb. 21丨Xintiandi (301277.SZ) announced that the company recently received the “Notice of Drug GMP Inspection Results from the Henan Drug Administration” issued by the Henan Drug Administration. The scope of the test is the active drug (moxifloxacin hydrochloride). After the review, the company basically complied with the requirements of the “Pharmaceutical Production Quality Management Code (2010 Revision)”. Moxifloxacin hydrochloride is a quinolone antibiotic used to treat infectious diseases caused by pathogens sensitive to this product, such as bacterial sinusitis, acute attacks of bacterial chronic bronchitis, community-acquired pneumonia, simple skin and skin tissue
Zhifu Resources Investment completed the issuance of HK$39 million convertible stock notes
Zhifu Resources Investment (00007) announced that all preconditions to the subscription agreement (as amended by the supplementary agreement dated January 24, 2024) have been fulfilled, and completed on February 1, 2024 in accordance with the terms and conditions of the subscription agreement (as supplemented by the supplementary agreement dated January 24, 2024). Convertible notes with a total principal amount of HK$39 million have been issued to Gaozhou Longyuan Xintiandi Real Estate Development Co., Ltd. (subscriber).
No Data
No Data